FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132871252> ?p ?o ?g. }

• W2132871252 endingPage "1208" @default.
• W2132871252 startingPage "1204" @default.
• W2132871252 abstract "BackgroundTo test the hypothesis that prognostication of treatment outcome is feasible by biomarker response at midcourse of chemoradiotherapy (CRT)/radiotherapy (RT), with respect to the plasma load of Epstein–Barr viral (EBV) DNA in nasopharyngeal carcinoma (NPC).Patients and methodsOne hundred seven patients with stage IIB–IV NPC were prospectively studied. Plasma EBV DNA load was measured by quantitative PCR before therapy (pre-DNA), at completion of 4 weeks of CRT/RT (mid-DNA), and within 3 months of completion of therapy (post-DNA). The end points are post-DNA load, a recognized surrogate of survival, and clinical outcome.ResultsNinety-three percent of patients had detectable EBV DNA before therapy (median load = 972 copies/ml). EBV DNA became undetectable in 55 (51%) patients at the end of week 4 of therapy. Detectable mid-DNA was associated with worse clinical outcome (median follow-up time, 6.2 years), for distant failure [hazard ratio (HR) 12.02, 95% confidence interval (CI) 2.78–51.93; P < 0.0001], progression-free survival (PFS; HR 4.05, 95% CI 1.89–8.67, P < 0.0001), and overall survival (OS; HR 3.29, 95% CI 1.37–7.90, P = 0.0077). Seventy-four percent of all failures were associated with detectable mid-DNA, whereas 34% of all failures were associated with detectable post-DNA. Stratification by tumor stage (IIB, III, IV) has no significant prognostic effect.ConclusionsUnfavorable EBV DNA response at midcourse of RT/CRT is an adverse prognosticator for treatment outcome, is linked to majority of all failures, and discriminates outcome better than tumor stage. The data could provide a basis for trial design that addresses alteration of therapy intensity during the latter phase of CRT, and adjuvant therapy. Validation studies are awaited." @default.
• W2132871252 created "2016-06-24" @default.
• W2132871252 creator A5005780854 @default.
• W2132871252 creator A5006443491 @default.
• W2132871252 creator A5023344499 @default.
• W2132871252 creator A5030823573 @default.
• W2132871252 creator A5033886818 @default.
• W2132871252 creator A5035845501 @default.
• W2132871252 creator A5038649839 @default.
• W2132871252 creator A5039149940 @default.
• W2132871252 creator A5040744782 @default.
• W2132871252 creator A5062767641 @default.
• W2132871252 creator A5090863040 @default.
• W2132871252 date "2014-06-01" @default.
• W2132871252 modified "2023-09-29" @default.
• W2132871252 title "Plasma Epstein–Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma" @default.
• W2132871252 cites W1814660981 @default.
• W2132871252 cites W1968017437 @default.
• W2132871252 cites W1969762178 @default.
• W2132871252 cites W1976598906 @default.
• W2132871252 cites W2019328052 @default.
• W2132871252 cites W2035947698 @default.
• W2132871252 cites W2071038583 @default.
• W2132871252 cites W2071879495 @default.
• W2132871252 cites W2120100820 @default.
• W2132871252 cites W2122582854 @default.
• W2132871252 cites W2125919881 @default.
• W2132871252 cites W2136147629 @default.
• W2132871252 cites W2149067175 @default.
• W2132871252 cites W2161043223 @default.
• W2132871252 doi "https://doi.org/10.1093/annonc/mdu117" @default.
• W2132871252 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24638904" @default.
• W2132871252 hasPublicationYear "2014" @default.
• W2132871252 type Work @default.
• W2132871252 sameAs 2132871252 @default.
• W2132871252 citedByCount "164" @default.
• W2132871252 countsByYear W21328712522014 @default.
• W2132871252 countsByYear W21328712522015 @default.
• W2132871252 countsByYear W21328712522016 @default.
• W2132871252 countsByYear W21328712522017 @default.
• W2132871252 countsByYear W21328712522018 @default.
• W2132871252 countsByYear W21328712522019 @default.
• W2132871252 countsByYear W21328712522020 @default.
• W2132871252 countsByYear W21328712522021 @default.
• W2132871252 countsByYear W21328712522022 @default.
• W2132871252 countsByYear W21328712522023 @default.
• W2132871252 crossrefType "journal-article" @default.
• W2132871252 hasAuthorship W2132871252A5005780854 @default.
• W2132871252 hasAuthorship W2132871252A5006443491 @default.
• W2132871252 hasAuthorship W2132871252A5023344499 @default.
• W2132871252 hasAuthorship W2132871252A5030823573 @default.
• W2132871252 hasAuthorship W2132871252A5033886818 @default.
• W2132871252 hasAuthorship W2132871252A5035845501 @default.
• W2132871252 hasAuthorship W2132871252A5038649839 @default.
• W2132871252 hasAuthorship W2132871252A5039149940 @default.
• W2132871252 hasAuthorship W2132871252A5040744782 @default.
• W2132871252 hasAuthorship W2132871252A5062767641 @default.
• W2132871252 hasAuthorship W2132871252A5090863040 @default.
• W2132871252 hasBestOaLocation W21328712521 @default.
• W2132871252 hasConcept C126322002 @default.
• W2132871252 hasConcept C142462285 @default.
• W2132871252 hasConcept C143998085 @default.
• W2132871252 hasConcept C146357865 @default.
• W2132871252 hasConcept C151730666 @default.
• W2132871252 hasConcept C203014093 @default.
• W2132871252 hasConcept C207103383 @default.
• W2132871252 hasConcept C2522874641 @default.
• W2132871252 hasConcept C2778424827 @default.
• W2132871252 hasConcept C2778997737 @default.
• W2132871252 hasConcept C2781197716 @default.
• W2132871252 hasConcept C44249647 @default.
• W2132871252 hasConcept C509974204 @default.
• W2132871252 hasConcept C55493867 @default.
• W2132871252 hasConcept C71924100 @default.
• W2132871252 hasConcept C86803240 @default.
• W2132871252 hasConcept C90924648 @default.
• W2132871252 hasConceptScore W2132871252C126322002 @default.
• W2132871252 hasConceptScore W2132871252C142462285 @default.
• W2132871252 hasConceptScore W2132871252C143998085 @default.
• W2132871252 hasConceptScore W2132871252C146357865 @default.
• W2132871252 hasConceptScore W2132871252C151730666 @default.
• W2132871252 hasConceptScore W2132871252C203014093 @default.
• W2132871252 hasConceptScore W2132871252C207103383 @default.
• W2132871252 hasConceptScore W2132871252C2522874641 @default.
• W2132871252 hasConceptScore W2132871252C2778424827 @default.
• W2132871252 hasConceptScore W2132871252C2778997737 @default.
• W2132871252 hasConceptScore W2132871252C2781197716 @default.
• W2132871252 hasConceptScore W2132871252C44249647 @default.
• W2132871252 hasConceptScore W2132871252C509974204 @default.
• W2132871252 hasConceptScore W2132871252C55493867 @default.
• W2132871252 hasConceptScore W2132871252C71924100 @default.
• W2132871252 hasConceptScore W2132871252C86803240 @default.
• W2132871252 hasConceptScore W2132871252C90924648 @default.
• W2132871252 hasIssue "6" @default.
• W2132871252 hasLocation W21328712521 @default.
• W2132871252 hasLocation W21328712522 @default.
• W2132871252 hasOpenAccess W2132871252 @default.
• W2132871252 hasPrimaryLocation W21328712521 @default.

• next